Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study

By sjmartinez • October 17, 2022

Wainberg ZA, Enzinger PC, Kang YK, Qin S, Yamaguchi K, Kim IH, Saeed A, Oh SC, Li J, Turk HM, Teixeira A, Borg C, Hitre E, Udrea AA, Cardellino GG, Sanchez RG, Collins H, Mitra S, Yang Y, Catenacci DVT, Lee KW. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2022 Oct 13:S1470-2045(22)00603-9. doi: 10.1016/S1470-2045(22)00603-9. Epub ahead of print. PMID: 36244398.

Tags: Digestive Diseases, Hematology/Oncology, Publications

Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with concurrent tacrolimus administration after lung transplant

Guimbellot JS, Chalamalla A, Baker E, Ryan KJ, Dowell A, Abouelenein S, Bartlett LE, Bergeron J, Turner G, Acosta EP, Ramos KJ. Elexacaftor-tezacaftor-ivacaftor pharmacokinetics with[...]

AGA Living Clinical Practice Guideline on Computer-Aided Detection-Assisted Colonoscopy

Sultan S, Shung DL, Kolb JM, Foroutan F, Hassan C, Kahi CJ, Liang PS, Levin TR, Siddique SM, Lebwohl B. AGA Living Clinical Practice Guideline[...]

Low Rates of Diagnosis and Treatment of Iron Deficiency Anemia After an Acute Severe Gastrointestinal Hemorrhage

Lin ES, Dutson U, Jensen DM. Low Rates of Diagnosis and Treatment of Iron Deficiency Anemia After an Acute Severe Gastrointestinal Hemorrhage. Dig Dis Sci.[...]